Posted by Michael Wonder on 20 Aug 2020
EMA agrees to review UCB's bimekizumab
18 August 2020 - Information about marketing authorisation application to EMA not yet disclosed by UCB.
The EMA has published a list of Applications for new human medicines under evaluation by the CHMP as at 6 August 2020.
The list notes a new application for bimekizumab. No other information about the application has been published. Last month, UCB issued a press release stating that bimekizumab superior to secukinumab in achieving complete psoriasis skin clearance.
